TaiMed Biologics Inc. reported earnings results for the second quarter and six months ended June 30, 2023. For the second quarter, the company reported sales was TWD 104.24 million compared to TWD 99.29 million a year ago. Net loss was TWD 47.84 million compared to TWD 75.77 million a year ago. Basic loss per share from continuing operations was TWD 0.19 compared to TWD 0.3 a year ago. Diluted loss per share from continuing operations was TWD 0.19 compared to TWD 0.3 a year ago.
For the six months, sales was TWD 176.01 million compared to TWD 139.96 million a year ago. Net loss was TWD 128.65 million compared to TWD 195.53 million a year ago. Basic loss per share from continuing operations was TWD 0.51 compared to TWD 0.77 a year ago. Diluted loss per share from continuing operations was TWD 0.51 compared to TWD 0.77 a year ago.